Clinical Trials Logo

BRCA2 Protein clinical trials

View clinical trials related to BRCA2 Protein.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00516373 Completed - Ovarian Neoplasms Clinical Trials

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Start date: July 11, 2005
Phase: Phase 1
Study type: Interventional

To determine the safety, tolerability, dose-limiting toxicity (DLT), pharmacokinetic-pharmacodynamic profile, and maximum tolerated dose (MTD) of KU-0059436 when administered orally to patients with advanced solid tumours. To further evaluate the safety and efficacy of KU-0059436 in an expanded cohort of BCRA-enriched population, primarily ovarian cancer patients